JP7130739B2 - 片頭痛の治療 - Google Patents

片頭痛の治療 Download PDF

Info

Publication number
JP7130739B2
JP7130739B2 JP2020519196A JP2020519196A JP7130739B2 JP 7130739 B2 JP7130739 B2 JP 7130739B2 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 7130739 B2 JP7130739 B2 JP 7130739B2
Authority
JP
Japan
Prior art keywords
leucine
migraine
pharmaceutically acceptable
acetyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526575A (ja
JP2020526575A5 (https=
Inventor
ストルップ マイケル
ファクター マロリー
Original Assignee
イントラビオ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7130739(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イントラビオ エルティーディー filed Critical イントラビオ エルティーディー
Publication of JP2020526575A publication Critical patent/JP2020526575A/ja
Publication of JP2020526575A5 publication Critical patent/JP2020526575A5/ja
Application granted granted Critical
Publication of JP7130739B2 publication Critical patent/JP7130739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020519196A 2017-06-14 2018-06-25 片頭痛の治療 Active JP7130739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
JP2020526575A JP2020526575A (ja) 2020-08-31
JP2020526575A5 JP2020526575A5 (https=) 2021-08-12
JP7130739B2 true JP7130739B2 (ja) 2022-09-05

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519196A Active JP7130739B2 (ja) 2017-06-14 2018-06-25 片頭痛の治療

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337081B2 (ja) * 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503658A (ja) 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
SI1867644T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP1664041B1 (en) * 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
PL1664016T3 (pl) * 2003-09-22 2009-04-30 Euro Celtique Sa Środki terapeutyczne przydatne do leczenia bólu
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2011162409A1 (en) * 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US10905670B2 (en) 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
FI3600276T3 (fi) 2017-03-28 2023-06-29 Intrabio Ltd Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
LT3697399T (lt) 2017-10-18 2026-01-12 Intrabio Ltd Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
JP7337081B2 (ja) 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
SI3989962T1 (sl) 2019-06-28 2025-11-28 Intrabio Ltd Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503658A (ja) 2006-09-13 2010-02-04 ピエール、ファーブル、メディカマン アセチル−ｌ−ロイシンによるめまいの治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Equilibrium Res.，2011年，Vol.70 No.3，pp.172-175
医学のあゆみ，2015年，Vol.255 No.7，pp.757-761

Also Published As

Publication number Publication date
CY1123860T1 (el) 2022-05-27
HUE053089T2 (hu) 2021-06-28
WO2018229738A1 (en) 2018-12-20
GB201709459D0 (en) 2017-07-26
RU2020100475A (ru) 2021-07-14
RS61481B1 (sr) 2021-03-31
CN111093772A (zh) 2020-05-01
ZA201908087B (en) 2024-11-27
PL3638370T3 (pl) 2021-05-17
RU2020100475A3 (https=) 2021-10-22
KR20210013518A (ko) 2021-02-04
AU2018284330B2 (en) 2024-03-14
SI3638370T1 (sl) 2021-04-30
CN111093772B (zh) 2023-11-03
ES2847169T3 (es) 2021-08-02
EP3638370A1 (en) 2020-04-22
HRP20210108T1 (hr) 2021-03-19
US11471434B2 (en) 2022-10-18
MA49396A (fr) 2020-04-22
IL271211B1 (en) 2023-09-01
MX2019014784A (es) 2021-11-16
DK3638370T3 (da) 2021-01-25
AU2018284330A1 (en) 2020-01-02
MD3638370T2 (ro) 2021-04-30
IL271211A (en) 2020-01-30
LT3638370T (lt) 2021-03-25
CA3067321A1 (en) 2018-12-20
EP3638370B1 (en) 2020-11-11
PT3638370T (pt) 2021-01-26
JP2020526575A (ja) 2020-08-31
US20200253905A1 (en) 2020-08-13
IL271211B2 (en) 2024-01-01
KR102594130B1 (ko) 2023-10-24
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396B1 (fr) 2021-03-31
SG11201912146RA (en) 2020-01-30
SMT202100037T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
JP7737367B2 (ja) α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法
KR102791288B1 (ko) 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
AU748993B2 (en) Pharmaceutical combinations containing tramadol
JP7130739B2 (ja) 片頭痛の治療
CA3079194A1 (en) Therapeutic agents for neurodegenerative diseases
WO2001000196A2 (en) Mirtazapine for weight gain in wasting diseases
RU2772278C2 (ru) Лечение мигрени
CA3067321C (en) Use of acetyle-leucine to prevent and/or treat migraine
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
HK40023292A (en) Treatment of migraine with acetyl-leucine
HK40023292B (en) Treatment of migraine with acetyl-leucine
JP2004505919A (ja) 一次性頭痛の処置におけるビタミン配合物の使用
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
HK1035143B (en) Pharmaceutical combinations containing tramadol for the production of a medicament for the treatment of migraine or migrainoid headaches

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220824

R150 Certificate of patent or registration of utility model

Ref document number: 7130739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250